Subscribe to stay informed!
A Malvern-based biotechnology company known for its gene therapies and vaccines, is expecting to raise $16.5 million through a public stock offering, writes…
Malvern-based Ocugen announced positive feedback for pediatric clinical testing of its version of the COVID-19 vaccine as the biopharmaceutical company attempts to bring…
Malvern-based Ocugen saw its stock soar after the FDA lifted its clinical hold on the company’s investigational new drug application to test the…
Malvern-based Ocugen, which is working to bring the Covaxin COVID-19 vaccine to the U.S., has entered into a deal to buy a…
Malvern-based Ocugen has submitted a request to the Food and Drug Administration for Emergency Use Authorization (EUA) of its COVID-19 vaccine candidate for…
Malvern-based Ocugen collaborated with India’s Bharat Biotech to develop a fourth vaccine, and it could be a game-changer in the ongoing fight…
Malvern-based Ocugen has finalized a deal with Bharat Biotech to develop the India-based company’s COVID-19 vaccine, Covaxin, for the U.S…
The decision to expand beyond gene therapy and sign a deal to co-develop a COVID-19 vaccine has turned out well for Malvern-based…
Malvern-based Ocugen saw its stock nearly triple last week after the company signed a letter of intent with Bharat Biotech to co-develop the…
Before we send you to this site, please subscribe to our daily newsletter.